Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT04913103 Not yet recruiting - Clinical trials for Lymphoma, Mantle-Cell

Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

CLSGMCLPOLA
Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

A Czech Lymphoma Study Group, phase II, open-label, study of polatuzumab-vedotin in combination with bendamustine and rituximab for patients with mantle cell lymphoma, who relapse after previous therapy with Bruton tyrosine kinase inhibitor

NCT ID: NCT04911478 Enrolling by invitation - Clinical trials for Lymphoma, Non-Hodgkin

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Start date: February 14, 2022
Phase:
Study type: Observational

The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.

NCT ID: NCT04910594 Recruiting - Lymphoma Clinical Trials

Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma

Start date: April 1, 2021
Phase: Phase 3
Study type: Interventional

The incidence of lymphoma and anemia is high and the clinical harm is great.However, it has not yet attracted enough clinical attention, and domestic rHuEPO (trade name: Ebio).Shenyang Sansheng Pharmaceutical Co., Ltd.) for lymphoma and anemia patients are less clinical studies.Therefore, a prospective, open-label, multicenter clinical study of recombinant human erythropoietin in the treatment of anemia in patients with lymphoma is planned to analyze the efficacy and safety of recombinant human erythropoietin in patients with lymphoma and anemia, so as to determine the clinical benefits of recombinant human erythropoietin in patients with lymphoma and anemia.

NCT ID: NCT04908059 Recruiting - Anaplastic Lymphoma Clinical Trials

Leukemic Phase of ALCL

LEUK-ALCL
Start date: January 27, 2021
Phase:
Study type: Observational

Collecting data about the rare leukemic presentation of anaplastic lymphoma to study the characteristics of patients with leukemic phase of ALCL

NCT ID: NCT04906902 Recruiting - Clinical trials for Central Nervous System Lymphoma

Acalabrutinib in CNSL

Start date: August 23, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is a Phase 1/2 clinical trial testing the safety, tolerance and efficacy of the drug Acalabrutinib for people with recurrent or refractory central nervous system lymphoma (CNSL).

NCT ID: NCT04906096 Recruiting - Clinical trials for Primary Central Nervous System Lymphoma

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)

NCT ID: NCT04904588 Recruiting - Lymphoma Clinical Trials

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

ACCESS
Start date: September 30, 2021
Phase: Phase 2
Study type: Interventional

This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic malignancies.

NCT ID: NCT04903197 Recruiting - Clinical trials for Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Start date: January 24, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of VAY736 alone or in combination with other therapies in patients with NHL in a platform trial.

NCT ID: NCT04899570 Recruiting - Clinical trials for Intravascular Large B-Cell Lymphoma

Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

This is a prospective single-arm phase II study, and the purpose of this study is to evaluate the efficiency of zanubrutinib combined with R-CHOP regimen in newly diagnosed primary intraocular lymphoma. Progression-free survival (PFS) of the cohort is the primary endpoint.

NCT ID: NCT04899453 Recruiting - Clinical trials for Primary Vitreoretinal Lymphoma

Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL

Start date: August 1, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective single-arm phase II study, and the purpose of this study is to evaluate the efficiency of ZR regimen (rituximab & Zanubrutinib) combined with intravitreal methotrexate and followed by Zanubrutinib maintenance in newly-diagnosed primary intraocular lymphoma. Progression-free survival (PFS) of the cohort is the primary endpoint.